Please enable JavaScript to continue using this application.

Compare $CATX vs $LRMR | Chartloom

Compare

$CATX vs $LRMR

Perspective Therapeutics Inc · Larimar Therapeutics Inc

CATX

Perspective Therapeutics Inc

LRMR

Larimar Therapeutics Inc

Compare $CATX vs $LRMR

Comparing Perspective Therapeutics Inc and Larimar Therapeutics Inc

CATXPerspective Therapeutics Inc

LRMRLarimar Therapeutics Inc

CATXPerspective Therapeutics Inc

Market cap

$303M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-66.9%

YTD performance

-4.7%

52W performance

-31.1%

FCF yield

-40.0%

LRMRLarimar Therapeutics Inc

Market cap

$277M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-23.1%

52W performance

-44.6%

FCF yield

-56.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CATX

LRMR

Detailed metrics comparison

CATX

Perspective Therapeutics Inc

LRMR

Larimar Therapeutics Inc

Market Cap

CATX$303M

LRMR$277M

Enterprise Value

CATX$256M

LRMR$185M

Price

CATX$2.66

LRMR$2.67

P/E Ratio

CATXN/A

LRMRN/A

P/S Ratio

CATX741.74x

LRMR0.00x

EV/Sales

CATX627.10x

LRMR0.00x

EV/EBITDA

CATX0.00x

LRMR0.00x

P/B Ratio

CATX0.97x

LRMR2.41x

P/FCF Ratio

CATXN/A

LRMRN/A

EV/FCF

CATX-2.11x

LRMR-1.18x

PEG Ratio

CATXN/A

LRMRN/A

Forward P/E (NTM)

CATXN/A

LRMRN/A

Forward P/S (NTM)

CATXN/A

LRMRN/A

Revenue (TTM)

CATX$409K

LRMR$0

Revenue Growth (YoY)

CATX-66.9%

LRMRN/A

Forward Rev Growth

CATX32.5%

LRMR290.4%

Gross Margin (TTM)

CATX23.0%

LRMR0.0%

Operating Margin (TTM)

CATX0.0%

LRMR0.0%

EBITDA Margin (TTM)

CATX-29628.1%

LRMR0.0%

Net Margin (TTM)

CATX-28468.0%

LRMR0.0%

FCF Margin (TTM)

CATX-29657.2%

LRMRN/A

Net Income (TTM)

CATX$-116M

LRMR$-173M

FCF (TTM)

CATX$-121M

LRMR$-156M

EPS (TTM)

CATX-$0.97

LRMR-$1.66

ROE (TTM)

CATX-4156.0%

LRMR-13739.0%

ROA (TTM)

CATX-3413.0%

LRMR-9765.0%

ROIC (TTM)

CATX-4132.0%

LRMR-13739.0%

Cash

CATX$48M

LRMR$93M

Debt

CATX$2M

LRMR$0

Net Cash/Debt

CATX$47M

LRMR$93M

Current Ratio (TTM)

CATX6.61x

LRMR4.70x

Quick Ratio (TTM)

CATX6.49x

LRMR4.58x

Debt/Equity (TTM)

CATX0.00x

LRMR0.00x

Debt/Assets (TTM)

CATX0.0%

LRMR0.0%

Interest Coverage (TTM)

CATXN/A

LRMRN/A

Net Debt/EBITDA (TTM)

CATX0.00x

LRMR0.00x

Beta

CATX1.87

LRMR0.68

52W Performance

CATX-31.1%

LRMR-44.6%

YTD Performance

CATX-4.7%

LRMR-23.1%

% from 52W High

CATX-56.8%

LRMR-58.4%

% from 52W Low

CATX35.7%

LRMR2.3%

Asset Turnover (TTM)

CATX0.00x

LRMR0.00x

FCF Yield (TTM)

CATX-40.0%

LRMR-56.3%

Earnings Yield (TTM)

CATX-38.4%

LRMR-62.2%

Dividend Yield (TTM)

CATXN/A

LRMRN/A

Rule of 40

CATX-29,724.1

LRMR0.0

EV/GP/RG

CATX22.31

LRMRN/A

Ticker research

View CATX research View LRMR research

Metric	CATX Perspective Therapeutics Inc	LRMR Larimar Therapeutics Inc
Market & Valuation
Market Cap	$303M	$277M
Enterprise Value	$256M	$185M
Price	$2.66	$2.67
P/E Ratio	N/A	N/A
P/S Ratio	741.74x	0.00x
EV/Sales	627.10x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	2.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.11x	-1.18x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$409K	$0
Revenue Growth (YoY)	-66.9%	N/A
Forward Rev Growth	32.5%	290.4%
Profitability
Gross Margin (TTM)	23.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-29628.1%	0.0%
Net Margin (TTM)	-28468.0%	0.0%
FCF Margin (TTM)	-29657.2%	N/A
Net Income (TTM)	$-116M	$-173M
FCF (TTM)	$-121M	$-156M
EPS (TTM)	-$0.97	-$1.66
ROE (TTM)	-4156.0%	-13739.0%
ROA (TTM)	-3413.0%	-9765.0%
ROIC (TTM)	-4132.0%	-13739.0%
Financial Health
Cash	$48M	$93M
Debt	$2M	$0
Net Cash/Debt	$47M	$93M
Current Ratio (TTM)	6.61x	4.70x
Quick Ratio (TTM)	6.49x	4.58x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.87	0.68
52W Performance	-31.1%	-44.6%
YTD Performance	-4.7%	-23.1%
% from 52W High	-56.8%	-58.4%
% from 52W Low	35.7%	2.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-40.0%	-56.3%
Earnings Yield (TTM)	-38.4%	-62.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-29,724.1	0.0
EV/GP/RG	22.31	N/A
Ticker research	View CATX research	View LRMR research

Valuation

P/S Ratio

LRMR

0.00x

CATX

741.74x

EV/FCF

CATX

-2.11x

LRMR

-1.18x

Growth & revenue

Revenue Growth TTM

CATX

-66.9%

Forward Revenue Growth

LRMR

290.4%

CATX

32.5%

Profitability & performance

Gross Margin

CATX

23.0%

LRMR

0.0%

ROE

CATX

-4156.0%

LRMR

-13739.0%

FCF Yield %

CATX

-40.0%

LRMR

-56.3%

52-Week Performance

CATX

-31.1%

LRMR

-44.6%

Detailed metrics comparison

CATX

Perspective Therapeutics Inc

LRMR

Larimar Therapeutics Inc

Market Cap

CATX$303M

LRMR$277M

Enterprise Value

CATX$256M

LRMR$185M

Price

CATX$2.66

LRMR$2.67

P/E Ratio

CATXN/A

LRMRN/A

P/S Ratio

CATX741.74x

LRMR0.00x

EV/Sales

CATX627.10x

LRMR0.00x

EV/EBITDA

CATX0.00x

LRMR0.00x

P/B Ratio

CATX0.97x

LRMR2.41x

P/FCF Ratio

CATXN/A

LRMRN/A

EV/FCF

CATX-2.11x

LRMR-1.18x

PEG Ratio

CATXN/A

LRMRN/A

Forward P/E (NTM)

CATXN/A

LRMRN/A

Forward P/S (NTM)

CATXN/A

LRMRN/A

Revenue (TTM)

CATX$409K

LRMR$0

Revenue Growth (YoY)

CATX-66.9%

LRMRN/A

Forward Rev Growth

CATX32.5%

LRMR290.4%

Gross Margin (TTM)

CATX23.0%

LRMR0.0%

Operating Margin (TTM)

CATX0.0%

LRMR0.0%

EBITDA Margin (TTM)

CATX-29628.1%

LRMR0.0%

Net Margin (TTM)

CATX-28468.0%

LRMR0.0%

FCF Margin (TTM)

CATX-29657.2%

LRMRN/A

Net Income (TTM)

CATX$-116M

LRMR$-173M

FCF (TTM)

CATX$-121M

LRMR$-156M

EPS (TTM)

CATX-$0.97

LRMR-$1.66

ROE (TTM)

CATX-4156.0%

LRMR-13739.0%

ROA (TTM)

CATX-3413.0%

LRMR-9765.0%

ROIC (TTM)

CATX-4132.0%

LRMR-13739.0%

Cash

CATX$48M

LRMR$93M

Debt

CATX$2M

LRMR$0

Net Cash/Debt

CATX$47M

LRMR$93M

Current Ratio (TTM)

CATX6.61x

LRMR4.70x

Quick Ratio (TTM)

CATX6.49x

LRMR4.58x

Debt/Equity (TTM)

CATX0.00x

LRMR0.00x

Debt/Assets (TTM)

CATX0.0%

LRMR0.0%

Interest Coverage (TTM)

CATXN/A

LRMRN/A

Net Debt/EBITDA (TTM)

CATX0.00x

LRMR0.00x

Beta

CATX1.87

LRMR0.68

52W Performance

CATX-31.1%

LRMR-44.6%

YTD Performance

CATX-4.7%

LRMR-23.1%

% from 52W High

CATX-56.8%

LRMR-58.4%

% from 52W Low

CATX35.7%

LRMR2.3%

Asset Turnover (TTM)

CATX0.00x

LRMR0.00x

FCF Yield (TTM)

CATX-40.0%

LRMR-56.3%

Earnings Yield (TTM)

CATX-38.4%

LRMR-62.2%

Dividend Yield (TTM)

CATXN/A

LRMRN/A

Rule of 40

CATX-29,724.1

LRMR0.0

EV/GP/RG

CATX22.31

LRMRN/A

Ticker research

View CATX research View LRMR research

Metric	CATX Perspective Therapeutics Inc	LRMR Larimar Therapeutics Inc
Market & Valuation
Market Cap	$303M	$277M
Enterprise Value	$256M	$185M
Price	$2.66	$2.67
P/E Ratio	N/A	N/A
P/S Ratio	741.74x	0.00x
EV/Sales	627.10x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	2.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.11x	-1.18x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$409K	$0
Revenue Growth (YoY)	-66.9%	N/A
Forward Rev Growth	32.5%	290.4%
Profitability
Gross Margin (TTM)	23.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-29628.1%	0.0%
Net Margin (TTM)	-28468.0%	0.0%
FCF Margin (TTM)	-29657.2%	N/A
Net Income (TTM)	$-116M	$-173M
FCF (TTM)	$-121M	$-156M
EPS (TTM)	-$0.97	-$1.66
ROE (TTM)	-4156.0%	-13739.0%
ROA (TTM)	-3413.0%	-9765.0%
ROIC (TTM)	-4132.0%	-13739.0%
Financial Health
Cash	$48M	$93M
Debt	$2M	$0
Net Cash/Debt	$47M	$93M
Current Ratio (TTM)	6.61x	4.70x
Quick Ratio (TTM)	6.49x	4.58x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.87	0.68
52W Performance	-31.1%	-44.6%
YTD Performance	-4.7%	-23.1%
% from 52W High	-56.8%	-58.4%
% from 52W Low	35.7%	2.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-40.0%	-56.3%
Earnings Yield (TTM)	-38.4%	-62.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-29,724.1	0.0
EV/GP/RG	22.31	N/A
Ticker research	View CATX research	View LRMR research